Werner Enterprises' Dr. Lanthaler Leads $3M Investment in aTENSION.life's Hypertension Diagnostics Innovation

Innovative Diagnostics for Hypertension: aTENSION.life Takes Center Stage

In a significant development for the healthcare sector, aTENSION.life announces the appointment of Dr. Werner Lanthaler, founder and CEO of Wlanholding GmbH, as Chairman of its Supervisory Board. This appointment coincides with a crucial seed financing round, where Wlanholding leads a $3 million investment alongside co-lead investors eQventure and VP Venture Partners. This funding marks a pivotal moment for aTENSION.life, a life science startup dedicated to advancing precision diagnostics for hypertension, a condition affecting approximately 1.3 billion adults worldwide.

The company's flagship product, the ALDO+PA test, is designed to screen for primary aldosteronism, a subtype of hypertension that remains significantly underdiagnosed, impacting 5-10% of patients. Dr. Lanthaler emphasizes the critical need for early and accurate diagnoses in hypertension management, noting that this funding will help make clinical mass spectrometry diagnostics more accessible to patients. Currently, the ALDO+PA test is offered in Austria through a partnership with labors.at and is set to expand its reach into the DACH markets—Germany, Austria, and Switzerland—by 2026. The initiative addresses a pressing global health issue, as many individuals suffer from hypertension without proper treatment due to the lack of awareness and diagnosis of specific subtypes.

Under Dr. Lanthaler's leadership, aTENSION.life aims to leverage its proprietary ALDO+ technology platform to transform how hypertension is diagnosed and treated. The management team, including CEO Bernhard Klemen, CSO Marko Poglitsch, and CBO Katharina Wieser, is well-equipped to drive this healthcare innovation. By focusing on precision diagnostics, aTENSION.life not only seeks to improve patient outcomes but also aims to address the significant market gap in hypertension diagnosis, thereby contributing to better health management strategies for millions globally.

In addition to its groundbreaking diagnostic technology, the collaboration with Wlanholding GmbH highlights an increasing trend in the life sciences sector, where investments in innovative startups are crucial for advancing healthcare solutions. The strategic guidance provided by Wlanholding, known for its focus on life sciences and sustainability, positions aTENSION.life for future growth and success in an increasingly competitive market.

As aTENSION.life prepares to launch its products in new markets, the company’s commitment to addressing hypertension's complex challenges stands to make a lasting impact on public health, offering hope to millions who currently lack adequate treatment options.